Predictive and prognostic significance of PIOS (Patras Immunotherapy Score) model in patients with advanced NSCLC treated with nivolumab or pembrolizumab: Results from a validation cohort.Foteinos-Ioannis D. Dimtrakopoulos,Giannis Socrates Mountzios,Petros Christopoulos,Thomas Papastergiou,Eleftherios Zervas,Sofia Agelaki,Epaminondas Samantas,Ilias Athanasiadis,Sofia Baka,Kostas N. Syrigos,Athina Christopoulou,Evangelos Lianos,Nikolaos Tsoukalas,Eleni Isidora Perdikouri,Georgios Oikonomopoulos,Foteini Kalofonou,Thomas Makatsoris,Angelos Koutras,Vasileios Megalooikonomou,Haralabos KalofonosJOURNAL OF CLINICAL ONCOLOGY（2021）引用 0|浏览5暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
